FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
BS Mann, JR Johnson, MH Cohen, R Justice… - The …, 2007 - academic.oup.com
BS Mann, JR Johnson, MH Cohen, R Justice, R Pazdur
The oncologist, 2007•academic.oup.comLearning Objectives After completing this course, the reader will be able to: Add vorinostat to
the armamentarium of drugs for CTCL. Identify the mechanism of action of vorinostat. Identify
goals of therapy of CTCL. Identify active CTCL therapies. Identify CTCL response criteria.
Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.
TheOncologist. com
the armamentarium of drugs for CTCL. Identify the mechanism of action of vorinostat. Identify
goals of therapy of CTCL. Identify active CTCL therapies. Identify CTCL response criteria.
Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.
TheOncologist. com
Learning Objectives
After completing this course, the reader will be able to:
- Add vorinostat to the armamentarium of drugs for CTCL.
- Identify the mechanism of action of vorinostat.
- Identify goals of therapy of CTCL.
- Identify active CTCL therapies.
- Identify CTCL response criteria.
Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Oxford University Press